Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which ...

In recent trading, shares of Scholar Rock Holding Corp (Symbol: SRRK) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.32/share. When a stock reaches ...

C AMBRIDGE, MA—Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold a portion of her holdings in the company. According to a filing with the ...

(RTTNews) - Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, Wednesday announced the appointment ...

Short interest in Scholar Rock Holding Corp (NASDAQ:SRRK) increased during the last reporting period, rising from 15.07M to 15.36M. This put 30.36% of the company's publicly available shares short.

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and ...